CTAD Lessons for 2020: More Phase 2 Trials, More Diversity

"Aaron Smith of Unlearn.AI, a startup company that uses machine learning to facilitate trials, suggested another way digital technology could cut enrollment. Machines can use data from the control arms of past trials to develop predictions for how disease will progress in a person depending on his or her baseline characteristics, he said. In effect, computers can generate a digital twin for each enrollee, describing what would likely happen to them without treatment. These digital twins can supplement the physical placebo group of a trial. This would lower the number of participants needed for a given trial, and allow a greater proportion of participants to receive drug rather than placebo. The chance of ending up in the placebo group deters many a potential participant."

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.
White Papers

Applications of Digital Twins in Clinical Trials for Alzheimer’s Disease

Press

Unlearn.AI named to the 2021 CB Insights AI 100 List of Most Innovative Artificial Intelligence Startups

Blog

Welcoming Dr. Taylor to Unlearn.AI’s Board of Directors

I’m honored to have such an inspirational and experienced leader like Dr. Taylor join our board.
The AI 100 is CB Insights' annual list of the 100 most promising private AI companies in the world.
How Digital Twins make it possible to design and run more efficient clinical trials with well-defined statistical properties.